DecisionDx-SCC Improves Risk-Stratification of SCC Patients Including Those in Various High-Risk Subgroups
Castle Biosciences, Inc.’s DecisionDx-SCC provides “significant, independent and clinically actionable risk-stratification” of Squamous cell carcinoma (SCC) patients including those in various high-risk subgroups, according to a study in Dermatology and Therapy. The DecisionDx-SCC test is a 40-gene expression profile test developed and validated to improve the accuracy of metastatic risk prediction for patients with high-risk […]